Literature DB >> 11104139

Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine.

P E Showalter1, D N Kimmel.   

Abstract

No medications clearly enhance consciousness or cognition following severe brain injury. This series (n = 13) suggests that lamotrigine may stimulate improvement of patients with impairment equivalent to level I-III on the Rancho Los Amigos Cognitive Scale. After a serendiptious clinical result, severely brain injured patients who were taking an anticonvulsant had an opportunity to start lamotrigine. This cohort had been transferred to this rehabilitation unit 14-304 (mean 73.9) days and started lamotrigine 20-310 (mean 87.5) days after acute brain injury. Compared to this unit's experience with patients with similar severe brain injuries, more patients (n = 10) were discharged to the conmmunity and fewer to skilled nursing facilities (n = 3) than were expected. This preliminary and provocative case series corresponds to basic science results, and further investigation of lamotrigine is warranted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104139     DOI: 10.1080/02699050050191931

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  5 in total

Review 1.  Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?

Authors:  Rosella Ciurleo; Placido Bramanti; Rocco Salvatore Calabrò
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 2.  Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?

Authors:  Francesca Pistoia; Elisa Mura; Stefano Govoni; Massimo Fini; Marco Sarà
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

3.  Posttraumatic seizures in survivors of torture: manifestations, diagnosis, and treatment.

Authors:  Alejandro Moreno; Michael Peel
Journal:  J Immigr Health       Date:  2004-10

Review 4.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 5.  The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications.

Authors:  Ryosuke Hanaya; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-02       Impact factor: 1.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.